Erratum: Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV (Virology (2004) 320 (167-180) DOI: 10.1016/j.virol.2003.12.003);Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV

Virology

Volumn 320, Issue 1, 2004, Pages 167-180

  Buckner, Clarisa ^a   Gines, Leoned G ^b   Saunders, Cheryl J ^b   Vojtech, Lucia ^b   Srivastava, Indresh ^c   Gettie, Agegnehu ^a,d   Bohm, Rudolph ^d   Blanchard, James ^d   Barnett, Susan W ^c   Safrit, Jeffrey T ^e,f   Stamatatos, Leonidas ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

Author keywords

Antibodies; CD8+ depletion; CTL; DNA immunization; HIV neutralization; Macaques; SHIVSF162P4; V2gp140

Indexed keywords

ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL MEDIATED LYMPHOLYSIS; CHIMERA; CONTROLLED STUDY; DISEASE COURSE; EVALUATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; INFECTION CONTROL; LONG TERM CARE; LYMPHOCYTE DEPLETION; MACACA; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SPECIES COMPARISON; VACCINATION; VIRUS ENVELOPE;

ANIMALIA; MACACA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 10744224172     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2004.05.002     Document Type: Erratum

References (52)

1. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.J., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. Control of a mucosal challenge and prevention of AIDS in rhesus macaques by a multiprotein DNA/MVA vaccine. Science. 8:2001;8.
2. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., O'Neil S.P., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McNicholl J.M., McClure H.M., Moss B., Robinson H.L. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89. 6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76(12):2002;6138-6146.
3. Amara R.R., Villinger F., Staprans S.I., Altman J.D., Montefiori D.C., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McClure H.M., Moss B., Robinson H.L. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76(15):2002;7625- 7631.
4. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6(2):2000;200-206.
5. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., Wang S., Mboudjeka I., Leung L., Lian Y., Fong A., Buckner C., Ly A., Hilt S., Ulmer J., Wild C.T., Mascola J.R., Stamatatos L. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75(12):2001;5526-5540.
6. Barouch H.D., Santra S., Schmitz J.E., Kuroda M.J., Fu T.-M., Wagner W., Bilska M., Craiu A., Zheng X.X., Krivulka G.R., Beaudry K., Lifton M.A., Nickerson C.E., Trigona W.L., Punt K., Freed D.C., Guan L., Dubey S., Casimiro D., Simon A., Davies M.-E., Chastain M., Strom T.B., Gelman R.S., Montefiori D.C., Lewis M.G., Emini E.A., Shiver J.W., Letvin N.L. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:2000;486-492.
7. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., Krivulka G.R., Beaudry K., Lifton M.A., Gorgone D.A., Montefiori D.C., Lewis M.G., Wolinsky S.M., Letvin N.L. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415(6869):2002;335-339.
8. Barouch D.H., Kunstman J., Glowczwskie J., Kunstman K.J., Egan M.A., Peyerl F.W., Santra S., Kuroda M.J., Schmitz J.E., Beaudry K., Krivulka G.R., Lifton M.A., Gorgone D.A., Wolinsky S.M., Letvin N.L. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J. Virol. 77(13):2003;7367-7375.
9. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D.R., Fenyo E.M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71(10):1997;7478-7487.
10. Burton D.R. Antibodies, viruses and vaccines. Nat. Rev., Immunol. 2(9):2002;706-713.
11. Cayabyab M., Karlsson G.B., Etemad-Moghadam B.A., Hofmann W., Steenbeke T., Halloran M., Fanton J.W., Axthelm M.K., Letvin N.L., Sodroski J.G. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). J. Virol. 73(2):1999;976-984.
12. Cherpelis S., Jin X., Gettie A., Ho D.D., Barnett S.W., Shrivastava I., Stamatatos L. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques. Immunol. Lett. 79(1-2):2001;47-55.
13. Cherpelis S., Shrivastava I., Gettie A., Jin X., Ho D.D., Barnett S.W., Stamatatos L. DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques. J. Virol. 75:2001;1547-1550.
14. Conley A.J., Kessler J.A. III, Boots L.N., McKenna P.M., Schleif W.A., Emini E.A., Mark G.E. III, Katinger H., Cobb E.K., Lunceford S.M., Rouse S.R., Murthy K.K. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:1996;6751-6758.
15. Connor R.I., Sheridan K.E., Ceradini D., Choe S., Landau N.R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185(4):1997;621-628.
16. Emini E.A., Schleif W.A., Nunberg J.H., Conley A.J., Eda Y., Tokiyoshi S., Putney S.D., Matsushita S., Cobb K.E., Jett C.M., Eichberg W.J., Murthy K.K. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (London). 355:1992;728-730.
17. Harouse J.M., Gettie A., Tan R.C., Blanchard J., Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science. 284(5415):1999;816-819.
18. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., Smith B.A., Baba T.W., Liska V., Ferrantelli F., Montefiori D.C., McClure H.M., Anderson D.C., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Katinger H., Stiegler G., Cavacini L.A., Posner M.R., Chou T.C., Andersen J., Ruprecht R.M. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75(16):2001;7470-7480.
19. Horton H., Vogel T.U., Carter D.K., Vielhuber K., Fuller D.H., Shipley T., Fuller J.T., Kunstman K.J., Sutter G., Montefiori D.C., Erfle V., Desrosiers R.C., Wilson N., Picker L.J., Wolinsky S.M., Wang C., Allison D.B., Watkins D.I. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76(14):2002;7187-7202.
20. Hu Q.X., Barry A.P., Wang Z.X., Connolly S.M., Peiper S.C., Greenberg M.L. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 74(24):2000;11858-11872.
21. Igarashi T., Brown C., Azadegan A., Haigwood N., Dimitrov D., Martin M.A., Shibata R. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat. Med. 5:1999;211-216.
22. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., Irwin C.E., Safrit J.T., Mittler J., Weinberger L., Kostrikis L.G., Zhang L., Perelson A.S., Ho D.D. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189(6):1999;991-998.
23. Johnson W.E., Lifson J.D., Lang S.M., Johnson R.P., Desrosiers R.C. Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J. Virol. 77(1):2003;375-381.
24. Koup R.A., Safrit J.A., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
25. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86(3):1996;367-377.
26. Long E.M., Rainwater S.M., Lavreys L., Mandaliya K., Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses. 18(8):2002;567-576.
27. Lu Y., Pauza C.D., Lu X., Montefiori D.C., Miller C.J. Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J. Acquired. Immune Defic. Syndr. Hum. Retrovirol. 19(1):1998;6-18.
28. Luciw P.A., Mandell C.P., Himathongkham S., Li J., Low T.A., Schmidt K.A., Shaw K.E., Cheng-Mayer C. Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques. Virology. 263(1):1999;112-127.
29. Marthas M.L., Lu D., Penedo M.C., Hendrickx A.G., Miller C.J. Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. AIDS Res. Hum. Retroviruses. 17(15):2001;1455-1466.
30. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., Katinger H., Birx D.L. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73(5):1999;4009-4018.
31. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6(2):2000;207-210.
32. Matano T., Shibata R., Siemon C., Connors M., Lane H.C., Martin M.A. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72:1998;164-169.
33. Michael N.L., Chang G., Louie L.G., Mascola J.R., Dondero D., Birx D.L., Sheppard H.W. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 3(3):1997;338-340.
34. Nishimura Y., Igarashi T., Haigwood N., Sadjadpour R., Plishka R.J., Buckler-White A., Shibata R., Martin M.A. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76(5):2002;2123-2130.
35. Parker R.A., Regan M.M., Reimann K.A. Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics. J. Virol. 75(22):2001;11234- 11238.
36. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75(17):2001;8340-8347.
37. Rasmussen R.A., Hofmann-Lehmann R., Li P.L., Vlasak J., Schmitz J.E., Reimann K.A., Kuroda M.J., Letvin N.L., Montefiori D.C., McClure H.M., Ruprecht R.M. Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. AIDS. 16(6):2002;829-838.
38. Reimann K.A., Tenner-Racz K., Racz P., Montefiori D.C., Yasumoto Y., Lin W., Ransil B.J., Letvin N.L. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J. Virol. 68:1994;2362-2370.
39. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.-W., Karlsson G.B., Sodroski J., Letvin N.L. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:1996;6922-6928.
40. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382(6593):1996;722-725.
41. Scarlatti G., Tresoldi E., Bjorndal A., Fredriksson R., Colognesi C., Deng H.K., Malnati M.S., Plebani A., Siccardi A.G., Littman D.R., Fenyo E.M., Lusso P. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3(11):1997;1259-1265.
42. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., Ghrayeb J., Forman M.A., Montefiori D.C., Rieber E.P., Letvin N.L., Reimann K.A. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283(5403):1999;857-860.
43. Schmitz J.E., Simon M.A., Kuroda M.J., Lifton M.A., Ollert M.W., Vogel C.W., Racz P., Tenner-Racz K., Scallon B.J., Dalesandro M., Ghrayeb J., Rieber E.P., Sasseville V.G., Reimann K.A. A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am. J. Pathol. 154(6):1999;1923-1932.
44. Schmitz J.E., Kuroda M.J., Santra S., Simon M.A., Lifton M.A., Lin W., Khunkhun R., Piatak M., Lifson J.D., Grosschupff G., Gelman R.S., Racz P., Tenner-Racz K., Mansfield K.A., Letvin N.L., Montefiori D.C., Reimann K.A. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 77(3):2003;2165-2173.
45. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:1999;204-210.
46. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415(6869):2002;331-335.
47. Srivastava I.K., VanDorsten K., Vojtech L., Barnett S.W., Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77(4):2003;2310-2320.
48. Stamatatos L., Cheng-Mayer C. An envelope modification that renders a primary, neutralization resistant, clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 72:1998;7840-7845.
49. Stamatatos L., Lim M., Cheng-Mayer C. Generation and structural analysis of soluble oligomeric envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV-1 isolates. AIDS Res. Hum. Retroviruses. 16:2000;981-994.
50. Ward R.H.R., Capon D.J., Jett C.M., Muthy K.K., Mordenti J., Lucas C., Frie S.W., Prince A.M., Green J.D., Eichberg J.W. Prevention of HIV-1 IIIb infection in chimpanzees by CD4 immunoadhesin. Nature (London). 352:1991;434-436.
51. Watson A., Ranchalis J., Travis B., McClure J., Sutton W., Johnson P.R., Hu S.L., Haigwood N.L. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J. Virol. 71(1):1997;284-290.
52. Zhang Y., Lou B., Lal R.B., Gettie A., Marx P.A., Moore J.P. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74(15):2000;6893-6910.